Evidence map›Paper›PMID 26288001›Full record

ArticleInflammatory bowel diseases2015

Alterations of the Subgingival Microbiota in Pediatric Crohn's Disease Studied Longitudinally in Discovery and Validation Cohorts.

Judith Kelsen, Kyle Bittinger, Helen Pauly-Hubbard, Leah Posivak, Stephanie Grunberg, Robert Baldassano, James D Lewis, Gary D Wu, Frederic D Bushman

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. The oral-gut microbiome axis in health and disease.Nature reviews. Microbiology · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Ulcerative Colitis Seems to Imply Oral Microbiome Dysbiosis.Current issues in molecular biology · 2022
    Article
  14. Review
  15. Article
  16. The role of oral bacteria in inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  17. mBio · 2021
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Judith Kelsen*Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; †Department of Microbiology; and ‡Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Kyle Bittinger
Helen Pauly-Hubbard
Leah Posivak
Stephanie Grunberg
Robert Baldassano
James D Lewis
Gary D Wu
Frederic D Bushman
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
Test-Treat strategy to prevent ulcerative colitis relapseK24DK078228 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LEWIS, JAMES D · 2007 to 2016
$1.9M
Diet, Genetic Factors, and the Gut Microbiome in Crohn's DiseaseUH3DK083981 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, LEWIS, JAMES D · 2011 to 2012
$1.7M
Purchase of the Roche GS SLX Sequencing SystemS10RR024525 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D · 2008 to 2008
$500k
NCRR NIH HHS S10 RR024525NCRR NIH HHS S10RR024525NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1RR024134NIAID NIH HHS P30 AI 045008NIAID NIH HHS P30 AI045008NIDDK NIH HHS K24 DK078228NIDDK NIH HHS K24-DK078228NIDDK NIH HHS P30 DK050306NIDDK NIH HHS UH3 DK083981NIDDK NIH HHS UH3DK083981
6 · The paper itself

Abstract

backgroundOral manifestations are common in Crohn's disease (CD). Here we characterized the subgingival microbiota in pediatric patients with CD initiating therapy and after 8 weeks to identify microbial community features associated with CD and therapy.

methodsPediatric patients with CD were recruited from The Children's Hospital of Pennsylvania. Healthy control subjects were recruited from primary care or orthopedics clinic. Subgingival plaque samples were collected at initiation of therapy and after 8 weeks. Treatment exposures included 5-ASAs, immunomodulators, steroids, and infliximab. The microbiota was characterized by 16S rRNA gene sequencing. The study was repeated in separate discovery (35 CD, 43 healthy) and validation cohorts (43 CD, 31 healthy).

resultsMost subjects in both cohorts demonstrated clinical response after 8 weeks of therapy (discovery cohort 88%, validation cohort 79%). At week 0, both antibiotic exposure and disease state were associated with differences in bacterial community composition. Seventeen genera were identified in the discovery cohort as candidate biomarkers, of which 11 were confirmed in the validation cohort. Capnocytophaga, Rothia, and TM7 were more abundant in CD relative to healthy controls. Other bacteria were reduced in abundance with antibiotic exposure among CD subjects. CD-associated genera were not enriched compared with healthy controls after 8 weeks of therapy.

conclusionsSubgingival microbial community structure differed with CD and antibiotic use. Results in the discovery cohort were replicated in a separate validation cohort. Several potentially pathogenic bacterial lineages were associated with CD but were not diminished in abundance by antibiotic treatment, suggesting targets for additional surveillance.

Indexed as

AdolescentAnti-Bacterial AgentsAnti-Inflammatory AgentsCapnocytophagaCase-Control StudiesChildChild, PreschoolCrohn DiseaseFemaleGastrointestinal AgentsGingivaGingival DiseasesHumansImmunologic FactorsInfliximabLongitudinal StudiesAnti-Bacterial AgentsAnti-Inflammatory AgentsGastrointestinal AgentsImmunologic FactorsInfliximabMesalamineRNA, Ribosomal, 16SSteroids

Identifiers

PMID26288001
PMCPMC4950860
OpenAlexW1132560470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.